{"type":"trials","record":{"id":41602,"source_id":"clinicaltrials-gov","external_id":"NCT07433088","title":"Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints","brief_summary":"Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease. Virtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Streetlab","enrollment":60,"countries":[],"start_date":"2026-04-01","completion_date":"2027-04-01","last_update_date":"2026-02-25","source_url":"https://clinicaltrials.gov/study/NCT07433088","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"VIRETTA","age_range":"50 Years","comparator":null,"organization":"Streetlab","interventions":["Object recognition and selection task"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Net selection assessed by the SPOT test — Baseline","Number of Net selection assessed by the SPOT test — Hour 1","Number of target selection assessed by the SPOT test — Baseline","Number of target selection assessed by the SPOT test — Hour 1"],"design_description":"NA · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["Dry AMD","Geographic Atrophy","Healhty","Object recognition and selection task"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07433088","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-04-01 to 2027-04-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.840Z","intervention":["Object recognition and selection task"],"participants":60,"study_design":"NA · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Net selection assessed by the SPOT test — Baseline","Number of Net selection assessed by the SPOT test — Hour 1","Number of target selection assessed by the SPOT test — Baseline","Number of target selection assessed by the SPOT test — Hour 1"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41602","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}